Evotec SE (EVO) stock
EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
$1.48−0.08 (-5.13%)
Close on Nov 17, 2026Market cap $526.23MP/E –Yield –
Evotec operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -€56.22M. The highest annual figure on record is €62.71M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€56.22M | – |
| FY2024 | Dec 31, 2024 | -€142.52M | – |
| FY2023 | Dec 31, 2023 | -€47.51M | -327.9% |
| FY2022 | Dec 31, 2022 | €20.85M | -49.1% |
| FY2021 | Dec 31, 2021 | €41.00M | -15.6% |
| FY2020 | Dec 31, 2020 | €48.56M | -22.6% |
| FY2019 | Dec 31, 2019 | €62.71M | – |
See a number that looks wrong?